Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 3/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15511200 | 0.82 | DGAT1 (0.44) | HDAC6HDAC1HDAC2CA12CA1 | |
| SCHEMBL12665879 | 0.78 | HDAC6 (0.35) | HDAC6HDAC1HDAC2 | |
| SCHEMBL16825071 | 0.78 | HDAC6 (0.35) | HDAC6HDAC1HDAC2 | |
| SCHEMBL19015410 | 0.77 | CYP4F2 (0.48) | CYP4F2CYP4A11PKMMMP8CA12 | |
| SCHEMBL16846576 | 0.77 | HDAC6 (0.34) | HDAC6HDAC1HDAC2 | |
| SCHEMBL22303932 | 0.77 | NFKB1 (0.43) | NFKB1NFKB2RELAHDAC6HDAC1 | |
| SCHEMBL25208979 | 0.76 | GAA (0.47) | CYP4F2CYP4A11PKMMMP8CA12 | |
| SCHEMBL15740510 | 0.76 | CYP4F2 (0.41) | CYP4F2CYP4A11HDAC6PKMMMP8 | |
| SCHEMBL24876166 | 0.76 | CA14 (0.39) | HDAC6HDAC1HDAC2 | |
| SCHEMBL19267523 | 0.75 | SMN1; SMN2 (0.40) | TSHRKDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| CN-110914254-A | Azole-substituted pyridine compound | 大正制药株式会社 | 2020-03-24 | — | — | CN | disclosed |
| EP-3083597-B1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES AS CAV2.2 CALCIUM CHANNEL BLOCKERS | GRUENENTHAL GMBH (DE) | 2017-11-22 | — | — | EP | disclosed |
| US-9562036-B2 | Fluoromethyl-substituted pyrrole carboxamides as CaV2.2 calcium channel blockers | Grünenthal GmbH (DE) | 2017-02-07 | — | — | US | disclosed |
| EP-3083612-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES AS CAV2.2 CALCIUM CHANNEL BLOCKERS | Grünenthal GmbH (DE) | 2016-10-26 | — | — | EP | disclosed |
| EP-3083597-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES III | Grünenthal GmbH (DE) | 2016-10-26 | — | — | EP | disclosed |
| US-20160289186-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES III | GRUENENTHAL GMBH (DE) | 2016-10-06 | — | — | US | disclosed |
| US-20160289214-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES AS CAV2.2 CALCIUM CHANNEL BLOCKERS | Grünenthal GmbH (DE) | 2016-10-06 | — | — | US | disclosed |
| WO-2015090603-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES III | Grünenthal GmbH (DE) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015090600-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES AS CAV2.2 CALCIUM CHANNEL BLOCKERS | Grünenthal GmbH (DE) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | CYP4F2 20/4885CYP4A11 2/4885NFKB1 987/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | CYP4F2 20/4885CYP4A11 2/4885NFKB1 987/4885 |
| US-20160289186-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES III | TRPV1, CACNA1B, CACNA1I | CYP4F2 2134/4885CYP4A11 4018/4885NFKB1 1429/4885 |
| US-20160289214-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES AS CAV2.2 CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNG2, CACNA1G | CYP4F2 1681/4885CYP4A11 4569/4885NFKB1 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.